Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors.
Umiker B, Hashambhoy-Ramsay Y, Smith J, Rahman T, Mueller A, Davidson R, Meyer C, Patankar G, Alam MM, Jaffe S, Krukenberg K, Goodman A, Spaulding V, Priess M, Dhaneshwar A, Wong M, Diiorio A, O'Malley K, McGrath L, Willer M, Pepper L, Gostissa M, Kis-Toth K, Wiederschain D, Cohen H, Shaffer DR.
Umiker B, et al. Among authors: willer m.
Mol Cancer Ther. 2023 Apr 3;22(4):471-484. doi: 10.1158/1535-7163.MCT-22-0351.
Mol Cancer Ther. 2023.
PMID: 36780212